Natixis’s Allogene Therapeutics ALLO Stock Holding History

Natixis’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-40,800	Closed	-$1.75M	–	734
2020 Q2	$1.75M	Buy	+40,800	New	+$1.48M	0.01%	440

Other funds holding ALLO

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Natixis's ALLO Position: Q3 2020 in Review

Natixis sold out of Allogene Therapeutics (ALLO) in Q3 2020, closing a stake of 40,800 shares — an estimated $1.75M sold.

Natixis first reported a position in ALLO in Q2 2020 and held it in 1 quarter. The position peaked at $1.75M in Q2 2020. 162 funds tracked by Wall St. Rank hold ALLO as of Q3 2020.

Natixis reported no remaining Allogene Therapeutics position as of Q3 2020 after selling out during the quarter.
Natixis sold 40,800 Allogene Therapeutics shares in Q3 2020, an estimated $1.75M.
Natixis first reported a position in Allogene Therapeutics in Q2 2020 and held it in 1 quarter.
Natixis's Allogene Therapeutics position peaked at $1.75M in Q2 2020.
162 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2020.

Based on Natixis's 13F filing for Q3 2020, filed 12 Nov 2020.